Retatrutide is an emerging triple hormone receptor agonist (GIP, GLP-1, and glucagon receptors), currently in clinical trials for treating obesity, type 2 diabetes, and metabolic disorders. It’s considered a next-generation weight loss drug—potentially more effective than both semaglutide and tirzepatide.